Comparison
Abacavir Hypersensitivity C5768819 vs 3p25 3 Microdeletion Syndrome C5437630
Clinical comparison between Abacavir Hypersensitivity and 3p25 3 Microdeletion Syndrome for differential diagnosis and treatment planning.
Abacavir Hypersensitivity C5768819
A potentially serious immune reaction to the HIV drug abacavir. Genetic testing is required before starting treatment to identify those at risk of this reaction.
3p25 3 Microdeletion Syndrome C5437630
A genetic condition from missing chromosome material at 3p25, linked to developmental delays, distinctive features, and sometimes heart or other organ involvement.
6 comparison axes
Onset
Abacavir Hypersensitivity C5768819
Variable
3p25 3 Microdeletion Syndrome C5437630
0-null
Onset patterns differ
Severity
Abacavir Hypersensitivity C5768819
severe
3p25 3 Microdeletion Syndrome C5437630
moderate
Different severity levels
Chronic
Abacavir Hypersensitivity C5768819
Acute
3p25 3 Microdeletion Syndrome C5437630
Chronic
Differing course
Communicable
Abacavir Hypersensitivity C5768819
No
3p25 3 Microdeletion Syndrome C5437630
No
Different transmission
Body System
Abacavir Hypersensitivity C5768819
immunologic
3p25 3 Microdeletion Syndrome C5437630
congenital
Same/different system
Category
Abacavir Hypersensitivity C5768819
immunologic
3p25 3 Microdeletion Syndrome C5437630
genetic
Different category
Bottom line
abacavir-hypersensitivity-C5768819 and 3p25-3-microdeletion-syndrome-C5437630 differ in severity, chronicity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | Abacavir Hypersensitivity C5768819 | 3p25 3 Microdeletion Syndrome C5437630 | Discriminating power |
|---|---|---|---|
| Timing of illness | Usually appears after abacavir exposure, often within weeks; exact timing varies. | Present from birth or early development; not drug-triggered. | High |
| Systemic features | May include fever, rash, and multi-organ symptoms; no single pattern is definitive. | Developmental delay and congenital features may occur; organ involvement is variable. | Moderate |
| Course | Acute and potentially severe; re-exposure can be dangerous. | Lifelong genetic condition with a chronic, variable course. | High |
When to favor each condition
Choose Abacavir Hypersensitivity C5768819 when
New symptoms after starting abacavir
Drug timing and immune features favor hypersensitivity over a congenital syndrome.
High
Positive HLA-B*5701 risk marker
This marker identifies higher risk and generally precludes abacavir use.
High
No lifelong developmental phenotype
Absence of congenital features supports a drug reaction if exposure fits.
Moderate
Choose 3p25 3 Microdeletion Syndrome C5437630 when
Congenital or early developmental concerns
Onset from birth or infancy fits a chromosomal condition, not abacavir exposure.
High
Microarray shows 3p25.3 deletion
A confirmed deletion supports the syndrome; clinical correlation remains necessary.
High
No relevant drug exposure
Without abacavir, hypersensitivity is not the appropriate explanation.
High
How key tests differ
| Test | Abacavir Hypersensitivity C5768819 | 3p25 3 Microdeletion Syndrome C5437630 | Interpretation |
|---|---|---|---|
| HLA-B*5701 testing | Used before abacavir to identify increased hypersensitivity risk. | Not diagnostic for this microdeletion. | A risk marker, not proof that symptoms are hypersensitivity. |
| Chromosomal microarray | Not used to diagnose abacavir hypersensitivity. | May detect missing material at 3p25.3. | Genetic confirmation still needs clinical interpretation. |
| Organ and laboratory evaluation | May show nonspecific inflammation or organ involvement during a reaction. | May assess heart or other organs when clinically indicated. | No universal cutoff distinguishes these conditions. |
Prognosis comparison
Abacavir Hypersensitivity C5768819
- Outcome
- Often improves after abacavir is stopped, but severe reactions can occur.
- Factors
- Prompt recognition, permanent avoidance, and HLA-B*5701 status.
3p25 3 Microdeletion Syndrome C5437630
- Outcome
- Chronic and variable; many need long-term developmental support.
- Factors
- Deletion extent, organ findings, and available therapies.
Time frame: Hours to weeks for the drug reaction; lifelong for the syndrome.
Published outcome data are limited; individual prognosis requires clinical assessment.
Complications comparison
| Complication | Presentation |
|---|---|
| Acute deterioration | Can become severe and may worsen with continued or repeated abacavir. Not an acute drug reaction; emergencies depend on associated anomalies. Exact complication rates are not established here. |
| Organ involvement | Multiple organs may be affected during hypersensitivity. Heart or other organs may be involved in some people. Involvement is variable and should not be assumed. |
| Long-term effects | Mainly related to the reaction and future drug avoidance. May include ongoing developmental and medical needs. Individual prognosis cannot be predicted from this comparison. |
Patient education highlights
- HighDifferent causes
One is a reaction to a specific HIV medicine; the other is a genetic chromosome change.
- HighAbacavir safety
Do not start or restart abacavir without clinician direction and appropriate genetic screening.
- MediumGenetic follow-up
A suspected microdeletion needs genetics review and individualized developmental care.